Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 25

    1.

    The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus.

    Garcia-Soria G, Gonzalez-Galvez G, Argoud GM, Gerstman M, Littlejohn TW 3rd, Schwartz SL, O'Farrell AM, Li X, Cherrington JM, Bennett C, Guler HP.

    Diabetes Obes Metab. 2008 Apr;10(4):293-300.PMID: 18333888 [PubMed - indexed for MEDLINE]Related articles

    2.

    Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.

    O'Farrell AM, van Vliet A, Abou Farha K, Cherrington JM, Campbell DA, Li X, Hanway D, Li J, Guler HP.

    Clin Ther. 2007 Aug;29(8):1692-705.PMID: 17919550 [PubMed - indexed for MEDLINE]Related articles

    3.

    Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study.

    Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, McIlwain HH, Heymsfield SB, Bray GA, Roberts WG, Heyman ER, Stambler N, Heshka S, Vicary C, Guler HP.

    JAMA. 2003 Apr 9;289(14):1826-32.PMID: 12684362 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Insulin-like growth factor-1 lowers protein oxidation in patients with thermal injury.

    Cioffi WG, Gore DC, Rue LW 3rd, Carrougher G, Guler HP, McManus WF, Pruitt BA Jr.

    Ann Surg. 1994 Sep;220(3):310-6; discussion 316-9.PMID: 8092898 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Clinical uses of insulin-like growth factor I.

    Bondy CA, Underwood LE, Clemmons DR, Guler HP, Bach MA, Skarulis M.

    Ann Intern Med. 1994 Apr 1;120(7):593-601. Review.PMID: 8116999 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients.

    Jabri N, Schalch DS, Schwartz SL, Fischer JS, Kipnes MS, Radnik BJ, Turman NJ, Marcsisin VS, Guler HP.

    Diabetes. 1994 Mar;43(3):369-74.PMID: 8314009 [PubMed - indexed for MEDLINE]Related articles

    7.

    Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus.

    Schalch DS, Turman NJ, Marcsisin VS, Heffernan M, Guler HP.

    J Clin Endocrinol Metab. 1993 Dec;77(6):1563-8.PMID: 8263142 [PubMed - indexed for MEDLINE]Related articles

    8.

    Hypoglycemic and insulin response to a continuous intravenous infusion of CGP-35126 recombinant human insulin-like growth factor-I (rhIGF-I) in healthy males.

    Morgan JM, Saris SD, Capuzzi DM, Good WR, John VA, Guler HP, Seaman J, Piraino AJ.

    J Clin Pharmacol. 1993 Apr;33(4):366-72.PMID: 8473552 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effects of insulin-like growth factor I on renal function in normal men.

    Hirschberg R, Brunori G, Kopple JD, Guler HP.

    Kidney Int. 1993 Feb;43(2):387-97.PMID: 8441234 [PubMed - indexed for MEDLINE]Related articles

    10.

    Recombinant human insulin-like growth factor I: effects in normal subjects and implications for use in patients.

    Guler HP, Wettstein K, Schurr W, Zapf J, Froesch ER.

    Adv Exp Med Biol. 1991;293:97-104. No abstract available. PMID: 1767745 [PubMed - indexed for MEDLINE]Related articles

    11.

    Regulation of binding proteins for insulin-like growth factors (IGF) in humans. Increased expression of IGF binding protein 2 during IGF I treatment of healthy adults and in patients with extrapancreatic tumor hypoglycemia.

    Zapf J, Schmid C, Guler HP, Waldvogel M, Hauri C, Futo E, Hossenlopp P, Binoux M, Froesch ER.

    J Clin Invest. 1990 Sep;86(3):952-61.PMID: 1697608 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Therapeutic potential of insulinlike growth factor i.

    Froesch ER, Guler HP, Schmid C, Binz K, Zapf J.

    Trends Endocrinol Metab. 1990 May-Jun;1(5):254-60.PMID: 18411128 [PubMed - in process]Related articles

    13.

    Effects of insulin-like growth factor I in man.

    Guler HP, Schmid C, Zapf J, Froesch ER.

    Acta Paediatr Scand Suppl. 1990;367:52-4.PMID: 2220389 [PubMed - indexed for MEDLINE]Related articles

    14.

    [Insulin-like growth factors (IGF I and IGF II) and diabetes]

    Froesch ER, Guler HP, Schmid C, Zapf J.

    Ther Umsch. 1990 Jan;47(1):8-14. Review. German. PMID: 2155481 [PubMed - indexed for MEDLINE]Related articles

    15.

    Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates.

    Guler HP, Zapf J, Schmid C, Froesch ER.

    Acta Endocrinol (Copenh). 1989 Dec;121(6):753-8.PMID: 2558477 [PubMed - indexed for MEDLINE]Related articles

    16.

    Insulin-like growth factor I regulates type I procollagen messenger ribonucleic acid steady state levels in bone of rats.

    Schmid C, Guler HP, Rowe D, Froesch ER.

    Endocrinology. 1989 Sep;125(3):1575-80.PMID: 2759033 [PubMed - indexed for MEDLINE]Related articles

    17.

    Small stature and insulin-like growth factors: prolonged treatment of mini-poodles with recombinant human insulin-like growth factor I.

    Guler HP, Binz K, Eigenmann E, Jäggi S, Zimmermann D, Zapf J, Froesch ER.

    Acta Endocrinol (Copenh). 1989 Sep;121(3):456-64.PMID: 2508389 [PubMed - indexed for MEDLINE]Related articles

    18.

    Insulin-like growth factor I increase glomerular filtration rate and renal plasma flow in man.

    Guler HP, Eckardt KU, Zapf J, Bauer C, Froesch ER.

    Acta Endocrinol (Copenh). 1989 Jul;121(1):101-6.PMID: 2741635 [PubMed - indexed for MEDLINE]Related articles

    19.

    Recombinant human insulin-like growth factor I induces its own specific carrier protein in hypophysectomized and diabetic rats.

    Zapf J, Hauri C, Waldvogel M, Futo E, Häsler H, Binz K, Guler HP, Schmid C, Froesch ER.

    Proc Natl Acad Sci U S A. 1989 May;86(10):3813-7.PMID: 2471192 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects.

    Guler HP, Schmid C, Zapf J, Froesch ER.

    Proc Natl Acad Sci U S A. 1989 Apr;86(8):2868-72.PMID: 2649897 [PubMed - indexed for MEDLINE]Related articlesFree article

    21.

    Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats.

    Guler HP, Zapf J, Scheiwiller E, Froesch ER.

    Proc Natl Acad Sci U S A. 1988 Jul;85(13):4889-93.PMID: 3387445 [PubMed - indexed for MEDLINE]Related articlesFree article

    22.

    Insulin-like growth factors in the Göttinger miniature-pig.

    Zenobi PD, Guler HP, Zapf J, Froesch ER.

    Acta Endocrinol (Copenh). 1988 Mar;117(3):343-52.PMID: 3289301 [PubMed - indexed for MEDLINE]Related articles

    23.

    Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults.

    Guler HP, Zapf J, Froesch ER.

    N Engl J Med. 1987 Jul 16;317(3):137-40.PMID: 3299085 [PubMed - indexed for MEDLINE]Related articles

    24.

    Growth restoration of insulin-deficient diabetic rats by recombinant human insulin-like growth factor I.

    Scheiwiller E, Guler HP, Merryweather J, Scandella C, Maerki W, Zapf J, Froesch ER.

    Nature. 1986 Sep 11-17;323(6084):169-71.PMID: 3528867 [PubMed - indexed for MEDLINE]Related articles

    25.

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Find related data

    Search details

    » See more...